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ABSTRACT 
Objectives- In vitro antioxidant activity assay is the preliminary step to determine a drug’s efficacy in combating oxidative stress when used in 
a clinical condition. The current study was aimed to determine the in vitro antioxidant activity of antidiabetic drug-SGLT-2 inhibitor 
(canagliflozin, dapagliflozin and empagliflozin) in combating the oxidative stress in diabetes mellitus. Methods- A total of five methods were 
adopted for determining the antioxidant potential of the drugs. The methods were DPPH radical scavenging assay, nitric oxide radical 
scavenging assay, phosphomolybdenum assay, assessment of inhibition of lipid peroxidation and FRAP. Results- The results indicated 
canagliflozin as best DPPH radical scavenger and empagliflozin as the best scavenger of nitric oxide radicals. Also, empagliflozin showed best 
reducing power and canagliflozin showed promising results in inhibiting lipid peroxidation. Conclusion- These findings suggest that use of 
canagliflozin and empagliflozin in diabetic patient will control the hyperglycemic conditions well as other complications that are caused by 
hyperglycemia induced oxidative stress. 
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INTRODUCTION 
Canagliflozin, dapagliflozin and empagliflozin are the three 
phlorizin derived drugs recently approved for the treatment 
of type 2 diabetes mellitus. These drugs selectively inhibit 
SGLT-2 in kidney without affecting the intestinal SGLT-1. 
SGLT-2, the main reabsorption transporter of glucose in 
nephron, if inhibited, is likely to cause an increase in urinary 
glucose excretion in individuals with type 2 diabetes 
mellitus. The lower plasma glucose and greater urinary 
glucose excretion leads to a net loss of calories and weight 
loss and also the increased glucose in urine produce a mild 
osmotic diuresis that may contribute to reduction in systolic 
blood pressure. As urinary glucose excretion is dependent 
on glomerular filtration rate, the gliflozin analogues is likely 
to be less effective in patients with impaired renal function. 
As these drugs increase the urinary glucose excretion, they 
often produce adverse effects like genital mycotic infection 
or urinary tract infection and some other adverse effects 
associated with osmotic diuresis. 
Our antioxidant defence system eliminates the reactive 
species (free radicals) and oxidative stress that occurs due to 
imbalance between production of free radicals and the 
reduced efficiency of antioxidant defence system against 
oxidants1. Amongst the various cause of diabetic 
complications, hyperglycaemia induced oxidative stress 
plays a key role2. Two main type of oxidants viz. reactive 
oxygen species includes free radicals like hydroxyl radicals 
(•OH), superoxide radicals (O2• -) & non-free radicals like 
peroxides and reactive nitrogen species includes free 
radicals like nitric oxide (•NO), nitrogen dioxide (NO2•-) & 
non-free radicals like peroxynitrite (OONO-)3 cause other 
complications like Parkinson’s disease4, Alzheimer’s 
Disease5, COPD6 and others that don’t have direct 
connections with diabetes. 
In type 2 diabetes mellitus, increased oxidative modification 
of plasma lipoprotein leads to increased peroxide lipid and 
lysophosphatidylcholine7 and the peroxide lipid is 
accumulated in cardiovascular tissue causing macrovascular 
damage8. Diminished expression of nitric oxide synthase and 
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generation of NO2, impaired expression of SOD, reduced 
level of antioxidant glutathione, α-tocopherol, ascorbate, 
hyperactivity of sorbitol pathway, enhanced protein 
glycosylation and AGE formation works all together in 
vascular endothelium to increase oxidative stress. Normal 
vascular endothelial functions are altered as a result and this 
is one of the pathogenic factor of vascular complications in 
several disease states including diabetes mellitus. 
The current study was focused on investigation of combating 
the oxidative stress or free radicals by canagliflozin, 
dapagliflozin and empagliflozin. The assessment of in vitro 
antioxidant activity was done in five methods. The methods 
employed were DPPH radical scavenging assay, nitric oxide 
radical scavenging assay, FRAP, phosphomolybdenum assay 
and assessment of inhibition of lipid peroxidation. 
MATERIALS AND METHODS 
Chemicals 
All the chemicals used were analytical grade. 2,2-diphenyl-1-
picrylhydrazyl (DPPH) was purchased from Himedia 
laboratories, Mumbai, India. L-ascorbic acid, methanol, 
sulphanilamide, N-(1-naphthyl)-ethyl-enediamine 
dihydrochloride, orthophosphoric acid, sodium, ethanol, 
hydrochloric acid, potassium ferrocyanide, ferric chloride, 
sodium dodecyl sulfate, ammonium molybdate, disodium 
hydrogen phosphate dihydrate, sulphuric acid, ferrous 
sulfate heptahydrate, glacial acetic acid, trichloroacetic acid, 
thiobarbituric acid and butan-1-ol were purchased from 
Merck, Mumbai, India. 
Determination of DPPH Radical Scavenging Assay 
The DPPH scavenging assay was performed for all the three 
drugs at concentration 50-800μg/ml against reference 
compound ascorbic acid by previously described method9 
with some modifications. The drugs were solubilized in 
suitable solvents with vortexing for five minutes or until 
complete solubilization. 50μL of the drug solutions of each 
concentration were taken in a test tube followed by addition 
of methanol up to 3 ml. 150μL of 0.13% w/v solution of 
DPPH in methanol was then added in each test tubes and 
sufficient time was provided for the antioxidant action to 
take place. The absorbance of the solution was measured 
with UV-visible spectrophotometer (Schimadzu UV-1800) at 
517 nm. The decrease in absorbance upon increasing drug 
concentration implicates more scavenging of free radicals. 
The % inhibition was calculated from the formula- 
% inhibition =      
                          
              
     
Determination of Nitric Oxide (NO) Scavenging Assay 
The method of Kang et al.,10 was followed for the 
determination of nitric oxide radical scavenging potential. 
5mM Sodium Nitropruside (SNP) in phosphate buffer saline 
pH 7.4 was used to generate NO which intermingles with 
oxygen to generate nitrite ions. Scavenging of the nitrite ions 
was assessed with Griess reagent (1% w/v sulphanilamide, 
5% w/v phosphoric acid, 0.1% w/v N-(1-naphthyl -ethyl-
enediamine dihydrochloride . 1ml of sodium nitropruside 
was added to each drug concentration ranging from 50-
800μg/ml followed by incubation at 25    at light for 60 
minutes and addition of equal volume of Griess reagent and 
incubation at same temperature at dark condition for 30 
minutes. The diazotization of nitrite ions with 
sulphanilamide and subsequent coupling reaction with N-(1-
naphthyl)-ethyl-enediamine dihydrochloride generates a 
pink chromophore, absorbance of which was measured at 
546 nm. The % inhibition was calculated using the same 
formula as used in DPPH radical scavenging assay process 
Ferric Ion Reduction by FRAP 
The method of Prieto et al11 was followed with some 
modifications. The principle behind this test is the ability of 
antioxidant to reduce Fe 3+ to Fe 2+ by electron donation. To 
the test tubes containing 100 μl drug solution with 
concentration ranging from 50-800 μl, 3 ml deionized water 
were added along with 90 μl of 95% ethanol. In the next 
step, addition of each of 150 μl of 1M HCl and 1% w/v 
potassium ferrocyanide was followed by addition of 50 μl of 
1% sodium dodecyl sulfate. Finally, 20 μl of 0.2% ferric 
chloride was added which imparts Prussian blue color. For 
proper distribution of color, all test tubes were vortexed for 
15 minutes. The absorbance was measured using UV-visible 
spectrophotometer (Schimadzu UV 1800) at 700 nm. The 
antioxidant activity of the drugs was evaluated taking 
ascorbic acid as standard. 
Phosphomolybdenum Assay   
The method of Prieto et al11 was followed with some 
modifications. The principle of phosphomolybdenum assay 
is the reduction of phosphate-Mo (VI) to phosphate-Mo (V) 
by antioxidants. Tubes containing 100 μL drug solution of 
varying concentration (50, 100, 200, 400 and 800 μg/ml  
were mixed with 1 ml deionized water and 1 ml of 
phosphomolybdenum reagent. Test tubes were labeled and 
heated at 95° C for 10 minutes. After cooling to room 
temperature, absorbances was taken at 695 nm. Antioxidant 
capacity was evaluated against standard antioxidant 
ascorbic acid. 
Assessment of Inhibition of Lipid Peroxidation 
Thiobarbituric Acid Reactive Substances (TBARS) method as 
described by Roberto et al12 was adopted with slight 
modification for the assessment of extent of inhibition of 
lipid peroxidation using egg yolk homogenate as lipid rich 
media. 500 μl of 10% egg yolk homogenate was added to 
tubes containing 100 μl of drug solution of concentration 
ranging from 50-800 μg/ml. The volume of the tubes was 
made 1 ml with deionized water. 50 μl of 0.07M ferrous 
sulfate was added to all the tubes and incubated for 20 
minutes to induce lipid oxidation. Then 1.5 ml of each of 
20% acetic acid and 0.8% w/v thiobarbituric acid prepared 
in 1.1% sodium dodecyl sulfate were added to all tubes 
followed by addition of 50 μl of 20% w/v trichloroacetic 
acid. Tubes were then vortexed and heated for 1 hour at 95° 
C. After cooling to room temperature, 5 ml of n-butanol was 
added to each test tubes and centrifuged at 5000 rpm for 5 
minutes. The organic upper layer was collected and 
absorbance was measured of each sample at 532 nm. The 
antioxidant capacity of the drugs was calculated as % 
inhibition taking ascorbic acid as standard. 
RESULT 
Determination of DPPH Radical Scavenging Assay  
A dose dependent DPPH radical scavenging activity was 
shown by ascorbic acid (figure-1) and all the gliflozin 
analogues. At 800 µg/ml concentration, extent of DPPH 
radicals scavenging by ascorbic acid, canagliflozin, 
dapagliflozin, empagliflozin (figure-2), was 97.87%, 
87.18±0.080%, 94.47±0.010% and 60.83±0.030%, 
respectively. The IC50 value shown by these drugs were 
117.4 ± 0.02, 103.6 ± 0.06, 130.1 ± 0.06 and 294.1 ± 0.04 
respectively for ascorbic acid, canagliflozin, dapagliflozin 
and empagliflozin (Table 4). 
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Figure 1: Standard curve of ascorbic acid in DPPH assay 
 
Figure 2: Antioxidant Potential of Gliflozin Analogues in DPPH assay 
Nitric Oxide Scavenging Method 
A dose dependent nitric oxide radical scavenging activity 
was established taking ascorbic acid as antioxidant (figure-
3). All the gliflozin also followed more or less similar pattern. 
At 800 µg/ml, the extent of NO radical scavenging by 
ascorbic acid, canagliflozin, dapagliflozin and empagliflozin 
(figure-4) was 87.16%, 66.77±0.140%, 68.23±0.080% and 
72.80±0.115% respectively. The IC50 data of ascorbic acid, 
canagliflozin, dapagliflozin and empagliflozin (table 4) were 
93.64 ± 0.115, 331.5 ± 0.16, 210.9 ± 0.19 and 92.71 ± 0.06.  
 
 
Figure 3: Standard curve of ascorbic acid in nitric oxide scavenging assay 
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Figure 4: Antioxidant Potential of Gliflozin Analogues in NO scavenging assay 
Ferric Ion Reduction by FRAP 
The dose dependent increase in radical scavenging activity 
of ascorbic acid measured by FRAP process is shown in 
figure-5. All the drugs followed similar dose dependent 
radical scavenging activity. At 800 µg/ml, the % RSA of 
ascorbic acid, canagliflozin, dapagliflozin and empagliflozin 
(figure-6) was found to be 98.47%, 74.18±0.080, 
90.22±0.105 and 94.70±0.085 respectively. The IC50 data 
shown by these drugs and ascorbic acid were 271.2 ± 0.06, 
350.6 ±0.09, 281.1 ±0.07, 264.1 ±0.16 (Table-4). 
 
 
Figure 5: Standard curve of ascorbic acid in ferric ion reduction by FRAP 
 
Figure 6: Antioxidant Potential of Gliflozin Analogues in ferric ion reduction by FRAP 
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Phosphomolybdenum Assay 
A dose dependent increase in antioxidant activity of ascorbic 
acid was found when the extent of antioxidant activity was 
measured by phosphomolybdenum assay process (figure-7). 
The similar pattern of antioxidant activity was observed for 
all drugs. At 800 µg/ml concentration, the extent of 
antioxidant activity shown by ascorbic acid, canagliflozin, 
dapagliflozin and empagliflozin (figure-8) was 99.36%, 
98.63±0.045, 98.07±0.110 and 99.30±0.085. Table 4 
contains IC50 values of all gliflozin analogues. The values 
were 174.3 ±0.04, 241.4 ±0.04, 344 ±0.11 and 272.3 ±0.07. 
  
 
Figure 7: Standard curve of ascorbic acid in phosphomolybdenum assay 
 
Figure 8: Antioxidant Potential of Gliflozin Analogues in phosphomolybdenum assay 
 
Assessment of Inhibition of Lipid Peroxidation 
The dose dependent increase in antioxidant power of 
ascorbic acid was established in the assessment of inhibition 
of lipid peroxidation (figure-9). The potential to inhibit the 
lipid peroxidation by ascorbic acid, canagliflozin, 
dapagliflozin and empagliflozin (figure-10), at concentration 
800 µg/ml was 98.31%, 85.46±0.035%, 81.39±0.065% and 
70.80±0.075% respectively. The IC50 values shown by 
ascorbic acid, canagliglozin, dapagliflozin and empagliflozin 
were 141.8±0.09, 207.5 ± 0.10, 243 ± 0.23, 264.6 ± 1.07 
(Table-4).
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Figure 9: Standard curve of ascorbic acid in inhibition of LPO assay 
 
Figure 10: Antioxidant Potential of Gliflozin Analogues in inhibition of LPO assay 
 
Statistical Analysis 
All samples were analyzed in sextuplicate and data are 
reported as Mean ± SEM. Statistical analysis was done with 
GraphPad Prism version 7. IC50 values were calculated taking 
concentration versus normalized response with variable 
slope in nonlinear regression. 
  
Table: 1 Free radical scavenging potential of Canagliflozin measured as % Inhibition 
Concentration 
μg/ml 
DPPH Nitric Oxide FRAP Phospho- 
molybdenum 
Lipid 
Peroxidation 
50 38.52±0.040c 28.42±0.060c 14.53±0.045c 6.78±0.110c 19.63±0.135b 
100 48.25±0.065c 32.72±0.075c 20.92±0.060b 25.41±0.075c 33.74±0.125c 
200 59.86±0.055b 38.73±0.220c 33.22±0.035ns 40.06±0.055c 49.57±0.075c 
400 73.54±0.075c 50.31±0.310c 51.10±0.110c 62.06±0.060c 59.51±0.110c 
800 87.18±0.080c 66.77±0.140c 74.18±0.080c 98.63±0.045a 85.46±0.035c 
Data are expressed as mean ± standard deviation (n = 4); mean in the same column with different superscripts are significantly 
different using unpaired two-tailed t-test at p <0.05. 
a = * p < 0.05, b = ** p < 0.01, c = *** p < 0.001, ns = nonsignificant p > 0.05 
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Table 2: Free radical scavenging potential of Dapagliflozin measured as % Inhibition 
Concentration 
μg/ml 
DPPH Nitric Oxide FRAP Phospho- 
molybdenum 
Lipid 
Peroxidation 
50 27.62±0.030c 36.54±0.050b 14.54±0.030c 3.22±0.040c 18.98±0.055b 
100 38.32±0.025c 41.23±0.085c 21.55±0.060c 6.90±0.085c 28.62±0.070c 
200 61.24±0.040c 47.75±0.110c 38.08±0.040c 20.97±0.055c 43.82±0.090c 
400 80.62±0.025c 53.90±0.075c 52.70±0.085c 55.57±0.115c 59.35±0.070c 
800 97.47±0.010b 68.23±0.080c 90.22±0.105c 98.07±0.110a 81.39±0.065c 
Data are expressed as mean ± standard deviation (n = 4); mean in the same column with different superscripts are significantly 
different using unpaired two-tailed t-test at p <0.05. 
a = * p < 0.05, b = ** p < 0.01, c = *** p < 0.001, ns = nonsignificant p > 0.05 
Table 3: Free radical scavenging potential of Empagliflozin measured as % Inhibition 
Concentration 
μg/ml 
DPPH Nitric Oxide FRAP Phospho- 
molybdenum 
Lipid 
Peroxidation 
50 37.37±0.015c 46.70±0.055c 11.41±0.080ns 3.15±0.060c 26.58±0.070b 
100 40.94±0.020c 50.20±0.020b 24.53±0.065c 16.78±0.105c 31.51±0.055c 
200 43.20±0.010c 54.08±0.110c 34.61±0.080a 37.08±0.04c 39.24±0.075c 
400 51.88±0.015c 61.08±0.135c 59.38±0.115b 59.34±0.075c 59.93±0.045c 
800 60.83±0.030c 72.80±0.115c 94.70±0.085c 99.30±0.085ns 70.80±0.075c 
Data are expressed as mean ± standard deviation (n = 4); mean in the same column with different superscripts are significantly 
different using unpaired two-tailed t-test at p <0.05. 
a = * p < 0.05, b = ** p < 0.01, c = *** p < 0.001, ns = nonsignificant p > 0.05 
Table 4: Tabular Representation of IC50 Value of Drugs and Standard 
Name DPPH 
Scavenging 
Nitric Oxide 
Scavenging 
FRAP Phospho- 
molybdenum 
Inhibition of LPO 
Ascorbic acid 117.4 ± 0.02 93.64 ± 0.115 271.2 ± 0.06 174.3 ±0.04 141.8±0.09 
Canagliflozin 103.6 ± 0.06c 331.5 ± 0.16c 350.6 ±0.09c 241.4 ±0.04c 207.5 ± 0.10c 
Dapagliflozin 130.1 ± 0.06c 210.9 ± 0.19c 281.1 ±0.07c 344 ±0.11c 243 ± 0.23c 
Empagliflozin 294.1 ± 0.04c 92.71 ± 0.06a 264.1 ±0.16c 272.3 ±0.07c 264.6 ± 1.07c 
Data are expressed as mean ± standard deviation (n = 4); mean in the same column with different superscripts are significantly 
different using unpaired two-tailed t-test at p <0.05. 
a = * p < 0.05, b = ** p < 0.01, c = *** p < 0.001, ns = nonsignificant p > 0.05 
 
DISCUSSION 
2,2-diphenyl-1-picrylhydrazyl (DPPH) is a stable nitrogen 
centred free radical widely used in the screening of 
antioxidant assay. Every antioxidant has some reducing 
property that can cause reduction of DPPH. After accepting 
one electron, hydrazyl group is converted to hydrazine and 
the deep violet colour of DPPH radical changes to light 
yellow, absorbance of which is measured at 517 nm. The 
decrease in absorbance indicates scavenging of DPPH free 
radicals by the antioxidant. All the gliflozin contains 4 
electron-rich hydroxyl group and at least one oxane ring. Due 
to this electron availability, gliflozins should have good 
antioxidant activity which is shown in table 1. The IC50 value 
of canagliflozin is lower than ascorbic acid which indicates 
canagliflozin as better antioxidant than the standard.  
The source of nitric oxide in human body is L-arginine and 
nitric oxide synthase13. In the structure of nitric oxide 
radical, the oxygen atom has a single unpaired electron. 
Scavengers of NO compete for cellular oxygen with L-
arginine and reduce the production of NO free radicals. The 
secondary process of generation of nitric oxide free radical is 
reaction between peroxy radical and NO14. Nitric oxide 
radical ultimately causes ischemia reperfusion, 
neurodegenerative disease like multiple sclerosis, and 
chronic inflammatory disease. Nitric oxide binds to the 
double bonds of carbon skeleton in lipid structure, and 
replace the hydrogen with its oxygen atom by breaking 
relatively weak carbon hydrogen bond. The oxygen atom 
forms peroxide compound which in turns generate more free 
radicals. Peroxidation in presence of nitric oxide generates a 
metabolite peroxynitrite (ONOO--) which is extremely 
reactive free radical. Peroxynitrite directly induce cytotoxic 
reactions like SH- group oxidation, lipid peroxidation, 
tyrosine nitration and DNA damage. Empagliflozin have the 
maximum number of electron lone pair in its structure, 
evidently it should have highest radical scavenging activity 
which is supported by table 1. 
FRAP method is a measurement of reducing power of a 
compound. Empagliflozin showed the best reducing power in 
this method. Dapagliflozin have almost equal reducing power 
as standard ascorbic acid. The greater the reducing power, 
the greater will be the tendency to lose electron. Loss of 
electron from a compound makes it oxidised, thus the drugs 
have well enough capability to prevent oxidative stress.  
Phosphomolybdenum assay measures the ability of drug to 
convert the yellow coloured complex phosphate-molybdate 
(VI) to green coloured complex phosphate-molybdate (V). 
This conversion involves a reduction reaction and so, 
phosphomolybdenum assay is a measure of the reducing 
power of the drug. Canagliflozin showed the best result, 
although significantly different from the standard ascorbic 
acid. However, the other drugs that should have shown 
better results showed significantly different results from 
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ascorbic acid. This may be due to the reaction rate of drugs 
and the phosphate-molybdate complex.  
Ferrous sulphate is used in egg yolk homogenate to induce 
lipid peroxidation. Free radicals generated in the system 
attack the carbon chain of the lipid and breaks it giving rise 
to malondialdehyde (MDA) and several aldehydes. These 
aldehydes form a pink chromophore with thiobarbituric acid. 
Reaction between thiobarbituric acid and the aldehydes is 
stopped by addition of trichloroacetic acid. In physiological 
system, MDA is the marker of lipid peroxidation. MDA is a 
highly reactive carbonyl compound that forms adducts with 
amino group of proteins and biomolecules. MDA also forms 
adducts with DNA base pairs which are mutagenic as well as 
carcinogenic. Drugs that effectively prevent the lipid 
peroxidation in egg yolk homogenate is expected to prevent 
peroxidation of brain phospholipid also. Canagliflozin 
showed a good potential to inhibit lipid peroxidation, 
although the extent of inhibition of lipid peroxidation of 
canagliflozin is little lower than ascorbic acid.  
The study indicates canagliflozin as the best inhibitor of lipid 
peroxidation and the antioxidant activity of canagliflozin is 
highest amongst the gliflozin analogues when measured by 
DPPH radical scavenging assay and phosphomolybdenum 
assay. The empagliflozin have the best antioxidant activity 
when measured by FRAP method and it is the best nitric 
oxide radical scavenger. Dapagliflozin have significant 
antioxidant activity as shown by DPPH radical scavenging 
assay and FRAP assay. So, canagliflozin and empaglifozin, 
when are in use clinically, they may elevate the quality of 
health of the patient by decreasing the diabetes induced 
oxidative stress and related complications. There may be a 
significant variation of these results in vivo as the 
therapeutic antidiabetic dose of the three drugs are 
different-canagliflozin 100 mg, dapagliflozin 10 mg and 
empagliflozin 25 mg15. So, the plasma drug concentration at 
normal therapeutic dose may vary and the antioxidant 
activity may also vary. Plasma protein binding is also a factor 
that may affect the in vivo results. The protein binding of 
canagliflozin is >99%16, 91% of dapagliflozin17 and 86.2% of 
empagliflozin18. The difference in plasma protein binding 
may affect the drug concentration in plasma and 
subsequently, the antioxidant activity. Further confirmation 
is required by investigating the in vivo antioxidant activity of 
these drugs. 
CONCLUSION 
The oxidative stress is a key factor for the propagation of 
diabetic neuropathy, diabetic retinopathy, diabetic 
nephropathy and other microvascular and macrovascular 
disease. All the three drugs i.e. Canagliflozin, Dapagliflozin, 
and Empagliflozin have promising antioxidant activity as 
compared to the standard antioxidant ascorbic acid. It can be 
suggested that empagliflozin and dapagliflozin can be 
employed clinically in oxidative stress induced diabetic 
complications besides their regular therapeutic approach. 
Moreover, some gliflozins analogues can contribute or 
enhance some of the potentiality of their efficacy by 
scavenging specific classes of toxic free radicals generated 
throughout the chronic diabetic stage. 
CONFLICT OF INTEREST 
The author declares no conflict of interest. 
REFERENCES 
1. Erejuwa, OO, Sulaiman SA, Wahab MS, Sirajudeen KN, Salleh 
MS, Gurtu S, Differential responses to blood pressure and 
oxidative stress in streptozotocin-induced diabetic wistar-
kyoto rats and spontaneously hypertensive rats: effects of 
antioxidant (honey) treatment. Int. J. Mol. Sci. 2011; 
12(3):1888-1907. 
2. Kangralkar VA, Patil SD, Bandivadekar RM, Oxidative stress 
and diabetes: a review. International Journal of 
Pharmaceutical Applications. 2010; 1(1):38-45. 
3. Halliwell B, Gutteridge JMC. Free Radicals in Biology and 
Medicine 4th ed. Clarendon Press, Oxford; 2007. 
4. Hyun DH, Lee M, Hattori N, Kubo S, Mizuno Y, Halliwell B, 
Jenner P, Effect of wild-type or mutant Parkin on oxidative 
damage, nitric oxide, antioxidant defenses, and the 
proteasome. J. Biol. Chem. 2002; 277: 28572–28577. 
5. Roberts LJ, Morrow JD, Measurement of F(2)-isoprostanes as 
an index of oxidative stress in vivo. Free Radic. Biol. Med. 
2000; 28: 505-513. 
6. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA, 
Chronic obstructive pulmonary disease is associated with an 
increase in urinary levels of iso- prostane F2alpha-III, an index 
of oxidant stress. Am. J. Respir. Crit. Care Med. 1998; 158: 
1709-1714. 
7. Takahara N, Kashiwagi A, Nishio Y, Oxidized lipoproteins 
found in patients with NIDDM stimulate radical-induced 
monocyte chemoattractant protein-1 mRNA expression in 
cultured human endothelial cells. Diabetologia. 1997; 40: 662–
670. 
8. Nishio Y, Kashiwagi A, Taki H, Altered activities of 
transcription factors and their related gene expression in 
cardiac tissues of diabetic rats. Diabetes. 1998; 47: 1318–
1325. 
9. Braca A, Sortino C, Politi M, Morelli I, Mendez J, Antioxidant 
activity of flavonoids from Licania licaniaeflora. J. 
Ethnopharmacol. 2001; 79: 379-381. 
10. Bajpai VK, Sharma A, Kang SC, Baek KH, Antioxidant, lipid 
peroxidation inhibition and free radical scavenging efficacy of 
a diterpenoid compound sugiol isolated from Metasequoia 
glyptostroboides. Asian Pac. J. Trop. Med. 2014; 9(15): 9-15 
11. Prieto P, Pineda M, Aguilar M, Spectrophotometric 
quantification of antioxidant capacity through the formation of 
a phosphomolybdenum complex: scientific application to the 
determination of vitamin E. Anal. Biochem. 1999; 269(2): 337-
341 
12. Roberto G, Baratta MT, Antioxidant activity of selected 
essential oil components in two lipid model system. Food. 
Chemistry. 2000; 69(2): 167–174 
13. Fang YZ, Yang S, Wu G, Free radicals, antioxidants, and 
nutrition. Nutrition. 2002; 18: 872-879. 
14. Noguchi N, Niki E, Chemistry of active oxygen species and 
antioxidants. In: Papas AM, editor. Antioxidant status, diet, 
nutrition, and health. Boca Raton: CRC Press; 1999: 3-20. 
15. Papadakis MA, McPhee SJ, Rabow MW, Current medical 
diagnosis and treatment. 55th ed. New York: McGraw Hill 
Education; 2016, p. 1202. 
16. https://www.drugbank.ca/drugs/DB08907 
17. https://www.drugbank.ca/drugs/DB06292 
18. https://www.drugbank.ca/drugs/DB09038
 
 
 
 
 
 
